Developer docs
API playgroundTry for free, no card

Search company profiles

Indena S.p.A.

Full company profile

uuid0007inl

Namestring
Indena S.p.A.
Legal namestring
Indena S.p.A.
Websiteurl
indena.com
Company typeenum
Private
Founded yearint
1921
Descriptiontext

Indena S.p.A. is a privately held, Milan-headquartered Italian company founded in 1921 and part of the IdB Holding group, specializing in the identification, development, and production of plant-derived active pharmaceutical ingredients, semi-synthetic APIs, and standardized botanical extracts. Its technical platform is anchored by the proprietary Indena Phytosome® delivery system — a food-grade lecithin-based solid dispersion technology with over 7 billion servings delivered globally, backed by approximately 100 patents and 100+ human clinical studies. Manufacturing capabilities extend to high-potency APIs with occupational exposure limits down to 1 ng/m³, peptide drug conjugate and antibody-drug conjugate production, GEA PSD2 spray drying, and 1,000–20,000 L multipurpose fermentation, with cGMP-certified sites in Settala and Palestro (Italy), Tours (France), and India, plus raw-material sourcing across 100+ plant species in 30+ countries. Differentiated traceability is delivered through DNA barcoding, an exclusive field-testing arrangement using Hyeshift's bCUBE® devices, and the proprietary IN-DNA certification mark.

The company sells primarily B2B into four end-markets: pharmaceutical companies (oncology APIs such as paclitaxel, docetaxel, cabazitaxel, and other semi-synthetic taxanes; central nervous system, cardiovascular, and anti-inflammatory APIs), nutraceutical and functional-food brands (branded Phytosome®-enabled ingredients including Quercefit®, Ubiqsome®, Meriva®, Mirtoselect®, Berbevis®, Centextra®, and 20+ other SKUs), cosmetics and personal care, and food & beverage. Distribution is direct enterprise sales through regional business representatives, supported by dedicated websites for the USA, Japan, and China, plus industry trade shows (CPHI, Vitafoods, DCAT, SupplySide). A growing third revenue stream is Contract Development and Manufacturing Organization services, including recent strategic alliances with Chemi S.p.A./Italfarmaco Group for peptide drug conjugates, TCG GreenChem for next-generation ADCs, Givaudan for beauty/wellness extracts, and Onegevity for AI-assisted indication discovery. Pricing is negotiated per inquiry and not publicly disclosed, and revenue figures are not reported. Headcount is in the 501–1,000 range, with 28% of staff in Quality and R&D, 95% on permanent contracts, and average tenure of 17 years.

Short descriptiontext

Indena S.p.A., founded in 1921 and headquartered in Milan, develops and manufactures plant-derived active pharmaceutical ingredients, botanical extracts, and Phytosome®-enhanced nutraceutical ingredients, selling B2B to global pharmaceutical, nutraceutical, cosmetic, and food companies alongside emerging CDMO services for HPAPIs, PDCs, and ADCs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMilano, Italy
HQ citystring
Milano
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
botanical active ingredients, pharmaceutical contract manufacturing, nutraceutical ingredient supply, plant-derived APIs, CDMO services
Industry5 codes
1Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts)
CodeAFAJAKADPrimaryYes
2Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
CodeEUAAAIAKPrimaryNo
3Clinical Trial Material (CTM) Manufacturing & Supply CDMO
CodeHLAGABAKPrimaryNo
4Antioxidants & Phytochemicals (Carotenoids, Tocopherols, Flavonoids, CoQ10, Resveratrol)
CodeAFAJAKAIPrimaryNo
5Herbal & Botanical Supplements
CodeCRADAGADPrimaryNo
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Botanical Pharmaceutical Ingredients
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Botanical Pharmaceutical Ingredients (APIs)
TypeOne Time License
Description

Sale of plant-derived and semi-synthetic active pharmaceutical ingredients to pharmaceutical companies for use in finished drug products. Includes oncology drugs (paclitaxel, docetaxel), cardiovascular, neurological, and anti-inflammatory compounds.

indena.com
2Nutraceutical Ingredients
TypeOne Time License
Description

Sale of standardized botanical extracts and proprietary Phytosome®-formulated ingredients to nutraceutical, functional food, cosmetic, and personal care companies.

indena.com
3CDMO (Contract Development and Manufacturing) Services
TypeProfessional Services
Description

Fee-for-service contract manufacturing and development services for biotech and pharmaceutical clients requiring complex API manufacturing, HPAPI production, and targeted therapeutic development (ADCs, PDCs).

clinicaltrialsarena.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 32 records shown
1Indena Phytosome®
Description

Proprietary technology platform that creates solid dispersions of phytonutrients within a food-grade lecithin matrix to improve bioabsorption of natural compounds

indena.com
+31 more records
Core offering1 text field

Indena S.p.A. identifies, develops, and produces plant-derived active pharmaceutical ingredients (APIs), standardized botanical extracts, and proprietary Phytosome®-formulated nutraceutical ingredients. The company also offers CDMO services for complex APIs, high-potency molecules (HPAPIs), and targeted therapeutics including peptide drug conjugates (PDCs) and antibody-drug conjugates (ADCs). Its portfolio spans oncology, cardiovascular, neurological, anti-inflammatory, and metabolic health APIs, alongside branded nutraceutical ingredients serving the supplement, functional food, and personal care industries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 7 billion servings of Phytosome® products delivered globally
+3 more records
Product overview1 text field

Indena S.p.A. is a Milan-based pharmaceutical and nutraceutical ingredient company founded in 1921, offering a comprehensive portfolio of botanical derivatives and CDMO services. The company's product portfolio includes over 100 pharmaceutical active ingredients (APIs) and nutraceutical products, organized into three main categories: (1) Proprietary Indena Phytosome® Technology Platform - a delivery system that improves bioabsorption of phytonutrients using food-grade lecithin matrices, with over 7 billion servings delivered globally; (2) Nutraceuticals - branded ingredients including Quercefit®, Ubiqsome®, Centextra®, Meriva®, Berbevis®, Mirtoselect®, and many others targeting health areas such as healthy aging, brain health, beauty from within, chronic ache relief, and weight management; (3) Pharmaceuticals - APIs including Paclitaxel, Docetaxel, Cabazitaxel, Voclosporin, and other botanical and semi-synthetic compounds for oncology, cardiovascular, and neurological applications. The company also provides CDMO services for complex APIs and targeted therapeutics including peptide drug conjugates.

Product and service14 records
1Indena Phytosome® Technology Platform
CategoryProprietary Technology Platform
Description

Proprietary delivery technology platform creating solid dispersions of phytonutrients within a food-grade lecithin matrix, significantly improving bioabsorption, enhancing gut microbiome interaction, and providing exceptional stability and safety for nutraceutical applications.

2CDMO Services for Complex APIs and Targeted Therapeutics
CategoryContract Development and Manufacturing
Description

Contract Development and Manufacturing Organization services providing integrated peptide drug conjugate (PDC) manufacturing, HPAPI production, and conjugation capabilities for biotech and pharmaceutical clients developing targeted therapeutics.

3Centextra®
CategoryNutraceutical Ingredient
Description

Innovative skin health solution combining Centella asiatica triterpenes with Indena Phytosome® technology, designed to reduce oxidative stress, rebalance inflammatory response, promote wound healing, and restore collagen levels.

4Berbevis®
CategoryNutraceutical Ingredient
Description

Berberine extract ingredient powered by Indena Phytosome® technology, supporting metabolic health and optimizing blood sugar and lipid profiles.

5Quercefit®
CategoryNutraceutical Ingredient
Description

Smart Indena Phytosome® quercetin formulation derived from Sophora japonica L. that helps slow down cellular aging through senolytic activity, backed by over 10 human studies.

6Ubiqsome®
CategoryNutraceutical Ingredient
Description

First CoQ10-based health-food ingredient formulated with Indena Phytosome® technology, with scientifically proven enhanced absorption and delivery into muscles, cells, and mitochondria supporting cellular energy production.

7Meriva®
CategoryNutraceutical Ingredient
Description

Curcumin ingredient formulated with Indena Phytosome® technology to optimize bioabsorption, backed by over 40 human studies supporting healthy inflammatory response in aging bodies.

8Mirtoselect®
CategoryNutraceutical Ingredient
Description

Bilberry extract from wild Vaccinium myrtillus with proprietary anthocyanin profile for antioxidant activity and neurological protection.

9Enovita® Organic
CategoryNutraceutical Ingredient
Description

Scientifically validated 100% organic grape seed extract rich in oligomeric proanthocyanidins, clinically proven to help maintain blood pressure within normal range and support cardiovascular wellbeing.

10Siliphos®
CategoryNutraceutical Ingredient
Description

Silybin from Silybum marianum formulated with Indena Phytosome® technology for liver health and antioxidant protection.

11Paclitaxel
CategoryPharmaceutical API
Description

Natural taxane-derived anticancer agent from Taxus baccata L. used in cancer chemotherapy, supplied as an active pharmaceutical ingredient to global pharmaceutical companies.

12Docetaxel
CategoryPharmaceutical API
Description

Semi-synthetic taxane anticancer agent derived from 10-deacetylbaccatin III used in cancer treatment, supplied as an active pharmaceutical ingredient.

13Colchicine
CategoryPharmaceutical API
Description

Antigout active pharmaceutical ingredient for treatment of gout and familial Mediterranean fever.

14Cannabidiol (CBD)
CategoryPharmaceutical API
Description

Pharmaceutical grade cannabinoid active pharmaceutical ingredient derived from Cannabis sativa L. for various therapeutic applications; first globally to secure European CEP certification.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Chemi S.p.A. / Italfarmaco Group
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-12
Description

Partnership to provide integrated peptide drug conjugate (PDC) manufacturing services, combining Chemi's peptide synthesis expertise with Indena's high-potency molecule and conjugation capabilities. Positions both companies as strategic development and manufacturing partners for biotech and pharmaceutical clients in the rapidly evolving targeted therapeutics field.

clinicaltrialsarena.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

Collaboration to develop innovative approaches for preventative health using Onegevity's AI platform to analyze botanical ingredients from Indena's portfolio to discover novel potential indications and beneficial effects for pharmaceutical and nutraceutical applications. Aims to identify strategies to reduce biological age versus chronological age and provide actionable personalized health solutions globally.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-28
Description

Strategic alliance to advance next-generation ADC (antibody-drug conjugate) technologies, combining Indena's HPAPI manufacturing and conjugation capabilities with TCG GreenChem's green chemistry expertise.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-12-26
Description

Partnership to advance plant-based extracts for the beauty and wellness sector, combining Givaudan's flavor and fragrance capabilities with Indena's botanical expertise.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to develop Enovita® Organic, a 100% organic grape seed extract combining Indena's botanical expertise with Alvinesa's natural antioxidant capabilities, delivering quality and sustainability in stress resilience ingredients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sabinsa is a privately held manufacturer of standardized botanical extracts and nutraceutical ingredients with a comparable branded-ingredient portfolio, similar science-led positioning, and overlapping pharma and supplement end-markets. Both companies compete head-to-head in categories like curcumin, boswellia, and berberine extracts.

TypeDirect peer
Description

Euromed produces standardized botanical extracts and natural APIs for the pharmaceutical and nutraceutical industries with cGMP manufacturing and clinical evidence backing. Its product portfolio (saw palmetto, milk thistle, tomato, cranberry) overlaps directly with Indena's branded nutraceutical range.

TypeBroad incumbent
Description

Through its Active Beauty and Taste & Wellbeing divisions, plus the Naturex acquisition, Givaudan is a global flavor, fragrance, and botanical ingredient incumbent that competes across many of Indena's nutraceutical and beauty-from-within categories. Givaudan is a current Indena partner (plant-based extracts for beauty), giving it both direct overlap and strategic familiarity.

TypeBroad incumbent
Description

DSM-Firmenich is a diversified nutrition, health, and ingredients conglomerate with an extensive botanical and nutraceutical portfolio, vitamin premixes, and CDMO-adjacent services. It competes with Indena across vitamins, carotenoids, polyphenol-based ingredients, and increasingly in CDMO/biotech-adjacent categories.

TypeDirect peer
Description

PLT Health Solutions is a US-based developer of branded, science-backed botanical and nutritional ingredients marketed to supplement brands, directly comparable to Indena's branded Phytosome® ingredient business. Both emphasize clinical validation, IP-protected ingredients, and B2B sales to nutraceutical formulators.

TypeBroad incumbent
Description

Kemin Industries is a diversified ingredient manufacturer with botanical, functional food, and personal-care product lines, including antioxidant, preservative, and specialty extract offerings that overlap with Indena's antioxidant and nutraceutical ingredients. Kemin's vertically integrated supply chain serves similar B2B channels.

TypeEmerging player
Description

Botanic Healthcare is an India-based manufacturer of standardized herbal extracts, phytopharmaceuticals, and nutraceutical ingredients with GMP-certified facilities. It is a comparable botanical-ingredient producer serving similar nutraceutical and supplement customers globally, especially in cost-sensitive segments.

TypeDirect peer
Description

Naturex (acquired by Givaudan) produces natural specialty ingredients including botanical extracts and phytoactives across nutraceutical, food, and personal-care markets. It historically competes with Indena in standardized botanical ingredients, though now owned by one of Indena's named partners.

TypeBroad incumbent
Description

Catalent is a major global CDMO providing development and manufacturing for biologics, oral and injectable dose forms, and cell/gene therapies. It is comparable to Indena's CDMO expansion into HPAPI and peptide drug conjugates from the CDMO services perspective, even though Catalent operates at meaningfully larger scale.

10Chemi S.p.A. (Italfarmaco Group)
TypeEmerging player
Description

Chemi S.p.A., part of Italfarmaco Group, is an Italian CDMO with expertise in peptide synthesis and is Indena's explicit partner for the integrated PDC manufacturing offering. As a partner-collaborator with overlapping customer bases in targeted therapeutics, Chemi is a directly comparable emerging CDMO in the peptide/HPAPI space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance13 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Indena S.p.A.

Botanical Pharmaceutical Ingredientsindena.com

Indena S.p.A., founded in 1921 and headquartered in Milan, develops and manufactures plant-derived active pharmaceutical ingredients, botanical extracts, and Phytosome®-enhanced nutraceutical ingredients, selling B2B to global pharmaceutical, nutraceutical, cosmetic, and food companies alongside emerging CDMO services for HPAPIs, PDCs, and ADCs.

What Indena S.p.A. does

Indena S.p.A. is a privately held, Milan-headquartered Italian company founded in 1921 and part of the IdB Holding group, specializing in the identification, development, and production of plant-derived active pharmaceutical ingredients, semi-synthetic APIs, and standardized botanical extracts. Its technical platform is anchored by the proprietary Indena Phytosome® delivery system — a food-grade lecithin-based solid dispersion technology with over 7 billion servings delivered globally, backed by approximately 100 patents and 100+ human clinical studies. Manufacturing capabilities extend to high-potency APIs with occupational exposure limits down to 1 ng/m³, peptide drug conjugate and antibody-drug conjugate production, GEA PSD2 spray drying, and 1,000–20,000 L multipurpose fermentation, with cGMP-certified sites in Settala and Palestro (Italy), Tours (France), and India, plus raw-material sourcing across 100+ plant species in 30+ countries. Differentiated traceability is delivered through DNA barcoding, an exclusive field-testing arrangement using Hyeshift's bCUBE® devices, and the proprietary IN-DNA certification mark.

The company sells primarily B2B into four end-markets: pharmaceutical companies (oncology APIs such as paclitaxel, docetaxel, cabazitaxel, and other semi-synthetic taxanes; central nervous system, cardiovascular, and anti-inflammatory APIs), nutraceutical and functional-food brands (branded Phytosome®-enabled ingredients including Quercefit®, Ubiqsome®, Meriva®, Mirtoselect®, Berbevis®, Centextra®, and 20+ other SKUs), cosmetics and personal care, and food & beverage. Distribution is direct enterprise sales through regional business representatives, supported by dedicated websites for the USA, Japan, and China, plus industry trade shows (CPHI, Vitafoods, DCAT, SupplySide). A growing third revenue stream is Contract Development and Manufacturing Organization services, including recent strategic alliances with Chemi S.p.A./Italfarmaco Group for peptide drug conjugates, TCG GreenChem for next-generation ADCs, Givaudan for beauty/wellness extracts, and Onegevity for AI-assisted indication discovery. Pricing is negotiated per inquiry and not publicly disclosed, and revenue figures are not reported. Headcount is in the 501–1,000 range, with 28% of staff in Quality and R&D, 95% on permanent contracts, and average tenure of 17 years.

Indena S.p.A. firmographics

Firmographics
Name
Indena S.p.A.
Legal name
Indena S.p.A.
Website
https://indena.com
Company type
Private
Founded year
1921
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Indena S.p.A., founded in 1921 and headquartered in Milan, develops and manufactures plant-derived active pharmaceutical ingredients, botanical extracts, and Phytosome®-enhanced nutraceutical ingredients, selling B2B to global pharmaceutical, nutraceutical, cosmetic, and food companies alongside emerging CDMO services for HPAPIs, PDCs, and ADCs.
Ownership category
akta.pro rank

Indena S.p.A. industry classification

Industry
Product category
Botanical Pharmaceutical Ingredients
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro primary industry
Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)
akta.pro secondary industries
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Antioxidants & Phytochemicals (Carotenoids, Tocopherols, Flavonoids, CoQ10, Resveratrol) (AFAJAKAI), Herbal & Botanical Supplements (CRADAGAD)

Keywords

  • Botanical active ingredients
  • Pharmaceutical contract manufacturing
  • Nutraceutical ingredient supply
  • Plant-derived APIs
  • CDMO services

Where Indena S.p.A. is headquartered

Location

Headquarters

HQ city
Milano
HQ country
Italy
HQ region
Europe

Offices8 records

Markets served

Indena S.p.A. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Botanical Pharmaceutical Ingredients (APIs): Sale of plant-derived and semi-synthetic active pharmaceutical ingredients to pharmaceutical companies for use in finished drug products. Includes oncology drugs (paclitaxel, docetaxel), cardiovascular, neurological, and anti-inflammatory compounds.
  2. Nutraceutical Ingredients: Sale of standardized botanical extracts and proprietary Phytosome®-formulated ingredients to nutraceutical, functional food, cosmetic, and personal care companies.
  3. CDMO (Contract Development and Manufacturing) Services: Fee-for-service contract manufacturing and development services for biotech and pharmaceutical clients requiring complex API manufacturing, HPAPI production, and targeted therapeutic development (ADCs, PDCs).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Indena S.p.A. product offering

Product offering

Core offering

Indena S.p.A. identifies, develops, and produces plant-derived active pharmaceutical ingredients (APIs), standardized botanical extracts, and proprietary Phytosome®-formulated nutraceutical ingredients. The company also offers CDMO services for complex APIs, high-potency molecules (HPAPIs), and targeted therapeutics including peptide drug conjugates (PDCs) and antibody-drug conjugates (ADCs). Its portfolio spans oncology, cardiovascular, neurological, anti-inflammatory, and metabolic health APIs, alongside branded nutraceutical ingredients serving the supplement, functional food, and personal care industries.

Product overview

Indena S.p.A. is a Milan-based pharmaceutical and nutraceutical ingredient company founded in 1921, offering a comprehensive portfolio of botanical derivatives and CDMO services. The company's product portfolio includes over 100 pharmaceutical active ingredients (APIs) and nutraceutical products, organized into three main categories: (1) Proprietary Indena Phytosome® Technology Platform - a delivery system that improves bioabsorption of phytonutrients using food-grade lecithin matrices, with over 7 billion servings delivered globally; (2) Nutraceuticals - branded ingredients including Quercefit®, Ubiqsome®, Centextra®, Meriva®, Berbevis®, Mirtoselect®, and many others targeting health areas such as healthy aging, brain health, beauty from within, chronic ache relief, and weight management; (3) Pharmaceuticals - APIs including Paclitaxel, Docetaxel, Cabazitaxel, Voclosporin, and other botanical and semi-synthetic compounds for oncology, cardiovascular, and neurological applications. The company also provides CDMO services for complex APIs and targeted therapeutics including peptide drug conjugates.

Differentiator

Problem solved

Functional benefit

Brands

  • Indena Phytosome®: Proprietary technology platform that creates solid dispersions of phytonutrients within a food-grade lecithin matrix to improve bioabsorption of natural compounds
  • Quercefit®
  • Ubiqsome®
  • Purebkale®
  • Meriva®
  • Mirtoselect®
  • Centextra®
  • Enovita®
  • Casperome®
  • Anthocran®
  • Siliphos®
  • Cronilief™
  • Mitidol®
  • Relissa™
  • Berbevis®
  • Vazguard®
  • Ginkgoselect® Plus
  • Leucoselect®
  • Greenselect®
  • Sabalselect®
  • Opextan®
  • Virtiva® Plus
  • Prodigest®
  • CUBO™
  • Beanblock®
  • Alextan®
  • Cinaran®
  • Bilear®
  • Lactolycopene
  • Polinacea®
  • Immunoselect®
  • Centevita®

Products and services

  • Indena Phytosome® Technology Platform Proprietary delivery technology platform creating solid dispersions of phytonutrients within a food-grade lecithin matrix, significantly improving bioabsorption, enhancing gut microbiome interaction, and providing exceptional stability and safety for nutraceutical applications.
  • CDMO Services for Complex APIs and Targeted Therapeutics Contract Development and Manufacturing Organization services providing integrated peptide drug conjugate (PDC) manufacturing, HPAPI production, and conjugation capabilities for biotech and pharmaceutical clients developing targeted therapeutics.
  • Centextra® Innovative skin health solution combining Centella asiatica triterpenes with Indena Phytosome® technology, designed to reduce oxidative stress, rebalance inflammatory response, promote wound healing, and restore collagen levels.
  • Berbevis® Berberine extract ingredient powered by Indena Phytosome® technology, supporting metabolic health and optimizing blood sugar and lipid profiles.
  • Quercefit® Smart Indena Phytosome® quercetin formulation derived from Sophora japonica L. that helps slow down cellular aging through senolytic activity, backed by over 10 human studies.
  • Ubiqsome® First CoQ10-based health-food ingredient formulated with Indena Phytosome® technology, with scientifically proven enhanced absorption and delivery into muscles, cells, and mitochondria supporting cellular energy production.
  • Meriva® Curcumin ingredient formulated with Indena Phytosome® technology to optimize bioabsorption, backed by over 40 human studies supporting healthy inflammatory response in aging bodies.
  • Mirtoselect® Bilberry extract from wild Vaccinium myrtillus with proprietary anthocyanin profile for antioxidant activity and neurological protection.
  • Enovita® Organic Scientifically validated 100% organic grape seed extract rich in oligomeric proanthocyanidins, clinically proven to help maintain blood pressure within normal range and support cardiovascular wellbeing.
  • Siliphos® Silybin from Silybum marianum formulated with Indena Phytosome® technology for liver health and antioxidant protection.
  • Paclitaxel Natural taxane-derived anticancer agent from Taxus baccata L. used in cancer chemotherapy, supplied as an active pharmaceutical ingredient to global pharmaceutical companies.
  • Docetaxel Semi-synthetic taxane anticancer agent derived from 10-deacetylbaccatin III used in cancer treatment, supplied as an active pharmaceutical ingredient.
  • Colchicine Antigout active pharmaceutical ingredient for treatment of gout and familial Mediterranean fever.
  • Cannabidiol (CBD) Pharmaceutical grade cannabinoid active pharmaceutical ingredient derived from Cannabis sativa L. for various therapeutic applications; first globally to secure European CEP certification.

Quantifiable outcome

  • Over 7 billion servings of Phytosome® products delivered globally
  • +3 more outcomes

Companies that use Indena S.p.A.

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Indena S.p.A. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Indena S.p.A. partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Chemi S.p.A. / Italfarmaco GroupcoreStrategic or Co-development Partner · 12 June 2026Partnership to provide integrated peptide drug conjugate (PDC) manufacturing services, combining Chemi's peptide synthesis expertise with Indena's high-potency molecule and conjugation capabilities. Positions both companies as strategic development and manufacturing partners for biotech and pharmaceutical clients in the rapidly evolving targeted therapeutics field.
  • Onegevity Health IntelligencecoreStrategic or Co-development Partner · 20 April 2026Collaboration to develop innovative approaches for preventative health using Onegevity's AI platform to analyze botanical ingredients from Indena's portfolio to discover novel potential indications and beneficial effects for pharmaceutical and nutraceutical applications. Aims to identify strategies to reduce biological age versus chronological age and provide actionable personalized health solutions globally.
  • TCG GreenChemcoreStrategic or Co-development Partner · 28 August 2025Strategic alliance to advance next-generation ADC (antibody-drug conjugate) technologies, combining Indena's HPAPI manufacturing and conjugation capabilities with TCG GreenChem's green chemistry expertise.
  • GivaudanminorStrategic or Co-development Partner · 26 December 2024Partnership to advance plant-based extracts for the beauty and wellness sector, combining Givaudan's flavor and fragrance capabilities with Indena's botanical expertise.
  • Alvinesa Natural IngredientsminorStrategic or Co-development PartnerCollaboration to develop Enovita® Organic, a 100% organic grape seed extract combining Indena's botanical expertise with Alvinesa's natural antioxidant capabilities, delivering quality and sustainability in stress resilience ingredients.

Scale indicators13 records

Recent moves6 records

Expansion highlights7 records

Indena S.p.A. competitors and assessment

Company assessment

Direct peers

  • Sabinsa (Sami-Sabinsa Group): Sabinsa is a privately held manufacturer of standardized botanical extracts and nutraceutical ingredients with a comparable branded-ingredient portfolio, similar science-led positioning, and overlapping pharma and supplement end-markets. Both companies compete head-to-head in categories like curcumin, boswellia, and berberine extracts.
  • Euromed (Euromed S.A.): Euromed produces standardized botanical extracts and natural APIs for the pharmaceutical and nutraceutical industries with cGMP manufacturing and clinical evidence backing. Its product portfolio (saw palmetto, milk thistle, tomato, cranberry) overlaps directly with Indena's branded nutraceutical range.
  • PLT Health Solutions: PLT Health Solutions is a US-based developer of branded, science-backed botanical and nutritional ingredients marketed to supplement brands, directly comparable to Indena's branded Phytosome® ingredient business. Both emphasize clinical validation, IP-protected ingredients, and B2B sales to nutraceutical formulators.
  • Naturex (Givaudan): Naturex (acquired by Givaudan) produces natural specialty ingredients including botanical extracts and phytoactives across nutraceutical, food, and personal-care markets. It historically competes with Indena in standardized botanical ingredients, though now owned by one of Indena's named partners.

Broad incumbents

  • Givaudan: Through its Active Beauty and Taste & Wellbeing divisions, plus the Naturex acquisition, Givaudan is a global flavor, fragrance, and botanical ingredient incumbent that competes across many of Indena's nutraceutical and beauty-from-within categories. Givaudan is a current Indena partner (plant-based extracts for beauty), giving it both direct overlap and strategic familiarity.
  • DSM-Firmenich: DSM-Firmenich is a diversified nutrition, health, and ingredients conglomerate with an extensive botanical and nutraceutical portfolio, vitamin premixes, and CDMO-adjacent services. It competes with Indena across vitamins, carotenoids, polyphenol-based ingredients, and increasingly in CDMO/biotech-adjacent categories.
  • Kemin Industries: Kemin Industries is a diversified ingredient manufacturer with botanical, functional food, and personal-care product lines, including antioxidant, preservative, and specialty extract offerings that overlap with Indena's antioxidant and nutraceutical ingredients. Kemin's vertically integrated supply chain serves similar B2B channels.
  • Catalent: Catalent is a major global CDMO providing development and manufacturing for biologics, oral and injectable dose forms, and cell/gene therapies. It is comparable to Indena's CDMO expansion into HPAPI and peptide drug conjugates from the CDMO services perspective, even though Catalent operates at meaningfully larger scale.

Emerging players

  • Botanic Healthcare: Botanic Healthcare is an India-based manufacturer of standardized herbal extracts, phytopharmaceuticals, and nutraceutical ingredients with GMP-certified facilities. It is a comparable botanical-ingredient producer serving similar nutraceutical and supplement customers globally, especially in cost-sensitive segments.
  • Chemi S.p.A. (Italfarmaco Group): Chemi S.p.A., part of Italfarmaco Group, is an Italian CDMO with expertise in peptide synthesis and is Indena's explicit partner for the integrated PDC manufacturing offering. As a partner-collaborator with overlapping customer bases in targeted therapeutics, Chemi is a directly comparable emerging CDMO in the peptide/HPAPI space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Indena S.p.A. social profiles

Digital presence

Indena S.p.A. compliance and trust

Trust signal

Compliance13 records

Indena S.p.A. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Indena S.p.A. leadership team

Management profile

Number of profiles

Profiles5 records

Indena S.p.A. subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Indena S.p.A. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Indena S.p.A. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indena S.p.A.

What does Indena S.p.A. do?

Indena S.p.A. identifies, develops, and produces plant-derived active pharmaceutical ingredients (APIs), standardized botanical extracts, and proprietary Phytosome®-formulated nutraceutical ingredients. The company also offers CDMO services for complex APIs, high-potency molecules (HPAPIs), and targeted therapeutics including peptide drug conjugates (PDCs) and antibody-drug conjugates (ADCs). Its portfolio spans oncology, cardiovascular, neurological, anti-inflammatory, and metabolic health APIs, alongside branded nutraceutical ingredients serving the supplement, functional food, and personal care industries.

Is Indena S.p.A. a public or private company?

Indena S.p.A. is a private company. It is classified as family owned and is currently operating.

When was Indena S.p.A. founded?

Indena S.p.A. was founded in 1921. It employs 501 to 1,000 people.

Where is Indena S.p.A. based?

Indena S.p.A. is headquartered in Milano, Italy, in the Europe region.

How does Indena S.p.A. make money?

Three revenue lines are on record. Botanical Pharmaceutical Ingredients (APIs) is the primary driver. The others are nutraceutical Ingredients and CDMO (Contract Development and Manufacturing) Services.

Who are Indena S.p.A.'s main competitors?

Direct peers on record are Sabinsa (Sami-Sabinsa Group), Euromed (Euromed S.A.), PLT Health Solutions and Naturex (Givaudan). Broad incumbents are Givaudan, DSM-Firmenich, Kemin Industries and Catalent. Emerging players are Botanic Healthcare and Chemi S.p.A. (Italfarmaco Group).

Does Indena S.p.A. have an API?

No public API is recorded for Indena S.p.A..

What industry is Indena S.p.A. in?

Indena S.p.A.'s product category is Botanical Pharmaceutical Ingredients. Its primary akta.pro industry code is AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts), with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyPeptide drug conjugates: How the Indena and Chemi partnership is deliveringIndena and Chemi S.p.A. / Italfarmaco Group have entered a partnership in which Chemi supplies peptides that Indena will conjugate with highly potent payload molecules, positioning both as development and manufacturing partners. Neither company is developing proprietary PDC drugs. The deal follows industry interest in peptide drug conjugates, with the ADC market growing from $1.6bn in 2017 to $13.6bn in 2024.Straits ResearchMilk Thistle Market Size, Share, Growth, Analysis, Forecast, 2034The global milk thistle market was valued at USD 1.75 billion in 2025 and is projected to grow to USD 3.70 billion by 2034 at a CAGR of 8.66%, driven by rising liver disorder prevalence and increasing consumer preference for herbal and plant-based supplements. North America held the largest regional market share at 31.29% in 2025, while the Asia Pacific region is expected to grow at the fastest CAGR of 10.84% during the forecast period. Key players in the market include NOW Foods, Nature's Way, Indena S.p.A., Martin Bauer Group, Euromed S.A., and Himalaya Wellness, who compete through standardized silymarin concentrations, advanced extraction technologies, and clinical validation.openPR.comNatural Tea Extract Market Evolves from Traditional Botanical Ingredient to Functional Wellness Infrastructure: Why Nutraceutical Demand, Functional Beverage Innovation, and Premium Organic PositioninFuture Market Insights released a market analysis projecting the global natural tea extract market to grow from USD 6.1 billion in 2026 to USD 12.7 billion by 2036, representing a CAGR of 7.5%, driven by functional nutrition demand, EGCG supplement growth, and organic certification trends. Green Tea Extract holds 45.0% of the product segment while Functional Beverages dominates applications at 50.0%, with China (10.13% CAGR) and India (9.38% CAGR) identified as the fastest-growing markets. The competitive landscape includes Naturex, Indena S.p.A, Kerry Group, Taiyo International, and Zhejiang Yinfeng Natural Products as leading players strengthening extraction technology and organic certification investments.Market Research & Business IntelligencePlant Based API MarketThe global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow from USD 4.2 billion in 2026 to USD 7.8 billion by 2036, representing a 6.4% CAGR, driven by regulatory support for natural compounds and rising demand for complex therapeutic molecules in oncology and chronic disease management. Amino acids lead product segments with 43.2% market share, while pharmaceuticals represent the largest application segment at 52.1%, reflecting the structural shift toward standardized botanical ingredients in drug development. Key growth markets include India (8.7% CAGR), China (7.2% CAGR), Germany (6.8% CAGR), USA (6.1% CAGR), and Brazil (5.9% CAGR), with leading players including Alchem International Ltd., Indena S.p.A., Naturex SA, DSM Nutritional Products, and Biocon Limited.Nutraceutical Business ReviewIndena curcumin phytosome supports kidney health, research saysIndena highlighted clinical evidence from the University of Milan and the University of Chieti-Pescara demonstrating that its Meriva curcumin phytosome supports kidney health by modulating oxidative stress and reducing inflammatory markers in patients with chronic and temporary kidney dysfunction. The studies confirmed that supplementation significantly improved albuminuria levels, balanced gut microbiota, and maintained a safe profile without adverse events over long-term use.Nutraceutical Business ReviewCognitive and metabolic health boosters: Indena presents its botanical range at Vitafoods EuropeIndena is presenting its range of botanical ingredients focused on cognitive and metabolic health at Vitafoods Europe 2024 in Geneva from May 14–16. The company showcased products such as Virtiva Plus, Berbevis, and Vazguard, which utilize its Phytosome technology to support brain function, stress tolerance, and metabolic balance.Nutraceutical Business ReviewIndena unveils advanced botanical solutions for healthy ageing at Vitafoods 2026Indena announced its participation in Vitafoods Europe 2026 to showcase a portfolio of botanical ingredients designed for healthy aging, including new products Centextra® and Purebkale®. The company highlighted the scientific validation and sustainability credentials of these extracts, which aim to support skin health, detoxification, and cellular vitality.Coherent Market InsightsBotanical Supplements Market Trends and Forecast, 2025-2032The global botanical supplements market is projected to grow from USD 122.18 billion in 2025 to USD 230.62 billion by 2032, driven by rising consumer demand for natural health solutions and preventive wellness. Key developments include DSM-Firmenich and Indena launching new biotic-botanical combinations, Apollo AyurVAID introducing certified herbal products in India, and BioVivo Science expanding production capacity in the U.S.EIN PresswireMedicinal Herbs Market to Reach USD 9.8 Bn by 2035, Fueled by Rising Preference for Natural Remedies | Fact.MR ReportAccording to a market research report by Fact.MR, the global medicinal herbs market is valued at USD 6.4 billion in 2025 and is projected to reach USD 9.8 billion by 2035, representing an absolute increase of USD 3.4 billion and a compound annual growth rate (CAGR) of 4.4%. The report attributes this growth to increasing consumer preference for natural remedies, integration of herbal ingredients into pharmaceuticals and nutraceuticals, and expanding applications in food, cosmetics, and personal care products. Recent product launches and facility expansions by Martin Bauer Group, Indena S.p.A., and Himalaya Wellness Company in 2024–2025 reflect active industry participation in capitalizing on this projected growth.Pharmaceutical TechnologyThe future of high-potency APIs: Strategies for manufacturingPharmaceutical companies are facing supply chain uncertainties and tariff risks regarding high-potency active pharmaceutical ingredients (HPAPIs) due to escalating friction between the US and China. Indena, a contract development and manufacturing organization, is positioning its Milan facility as a strategic solution by consolidating synthesis, fermentation, and extraction capabilities under one roof to ensure supply security. This integrated approach aims to meet the growing global demand for complex biologics and oncology treatments while mitigating risks associated with fragmented global production.